Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF.

J Nucl Med. 1999 Feb;40(2):302-10.

2.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF.

Anticancer Res. 1998 Jul-Aug;18(4B):2779-88.

PMID:
9713461
3.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.

J Nucl Med. 2000 May;41(5):952-8.

4.

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ.

Clin Cancer Res. 1999 Mar;5(3):533-41.

5.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3330s-3336s.

PMID:
10541382
6.

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ.

J Nucl Med. 1999 Dec;40(12):2014-20.

7.

Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).

DeNardo GL, Kukis DL, Shen S, Mausner LF, Meares CF, Srivastava SC, Miers LA, DeNardo SJ.

Clin Cancer Res. 1997 Jan;3(1):71-9.

8.

Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.

DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA.

Cancer. 1997 Dec 15;80(12 Suppl):2576-82.

PMID:
9406712
9.

Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.

J Nucl Med. 1999 Aug;40(8):1317-26.

10.
11.

Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.

Kroger LA, DeNardo SJ, DeNardo GL, Xiong CY, Winthrop MD, Gumerlock PH.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3010s-3014s.

PMID:
10541336
12.

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.

Mirick GR, O'Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL.

Nucl Med Biol. 1999 Oct;26(7):841-5.

PMID:
10628566
13.

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.

Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ.

Cancer Biother Radiopharm. 2001 Jun;16(3):213-25.

PMID:
11471486
14.

Antibody responses to macrocycles in lymphoma.

DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ.

J Nucl Med. 1996 Mar;37(3):451-6.

15.

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP.

J Clin Oncol. 1998 Oct;16(10):3246-56.

PMID:
9779698
16.

Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.

Connett JM, Anderson CJ, Guo LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ.

Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6814-8.

17.

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.

J Nucl Med. 2003 Mar;44(3):465-74.

18.

Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.

Shen S, DeNardo GL, DeNardo SJ, Salako Q, Morris G, Banks D, Yuan A, DeNardo DA.

J Nucl Med. 1996 Jan;37(1):146-50.

19.

Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.

Deshpande SV, DeNardo SJ, Meares CF, McCall MJ, Adams GP, Moi MK, DeNardo GL.

J Nucl Med. 1988 Feb;29(2):217-25.

20.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.

J Nucl Med. 2003 Dec;44(12):2000-18.

Items per page

Supplemental Content

Write to the Help Desk